title: Study on the effects of allitride and its mechanisms on renal cell carcinoma in vitro.
abstract: OBJECTIVE
  To study the killing effect of allitride on human renal cell carcinoma cell line Ketr-3 and its possible mechanisms.
  
  
  METHODS
  The Ketr-3 cells were treated with allitride and the morphological changes were observed with inverted microscope. The cytotoxicity was estimated through theamine blue tetrazolium bromide (MTT). Apoptotic cells were detected by in situ cell apoptosis detection kit, and confirmed by flow cytometry. Changes of apoptosis rate cell cycle were assessed by flow cytometry. Caspase-3 (cysteineaspartate specific proteinase) mRNA was detected by semi-quantitative reverse transcriptase polymerase chain reaction (RT-PCR), and Caspase-3 protease activity was estimated with colorimetry.
  
  
  RESULTS
  MTT assay and morphological changes confirmed the killing effect of allitride on Ketr-3 cellline. FCM also showed that S-phase and G2/M-phase arrest was induced. RT-PCR and colorimetry confirmed that there was apparently a rise of Caspase-3 mRNA and Caspase-3 protease activity.
  
  
  CONCLUSIONS
  Allitride could kill Ketr-3 effectively by inducing apoptosis. Cell cycle arrest and up-regulation of Caspase-3 may play an important role in the mechanisms of killing effect.
authors.affiliation: Department of Urology, Henan University Huaihe hospital, Kaifeng, 475000, China.
authors.forename: Hui
authors.initials: H
authors.lastname: Liu
authors.forename: Rong-pei
authors.initials: RP
authors.lastname: Wu
authors.forename: Xiao-fei
authors.initials: XF
authors.lastname: Li
authors.forename: Kai-yuan
authors.initials: KY
authors.lastname: Cao
authors.forename: Le-jun
authors.initials: LJ
authors.lastname: Li
authors.forename: Wei
authors.initials: W
authors.lastname: Zhang
mesh_terms: D000465:Algorithms; D000498:Allyl Compounds / Q000494:pharmacology* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D000975:Antioxidants / Q000494:pharmacology; D017209:Apoptosis / Q000187:drug effects*; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000201:enzymology; D053148:Caspase 3 / Q000096:biosynthesis / Q000187:drug effects / Q000378:metabolism*; D002453:Cell Cycle / Q000187:drug effects; D003124:Colorimetry; D005434:Flow Cytometry; D015971:Gene Expression Regulation, Enzymologic / Q000187:drug effects; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D006801:Humans; D066298:In Vitro Techniques; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D012333:RNA, Messenger / Q000187:drug effects; D020133:Reverse Transcriptase Polymerase Chain Reaction; D013440:Sulfides / Q000494:pharmacology* / Q000627:therapeutic use; D014407:Tumor Cells, Cultured
chemical_list: D000498:Allyl Compounds; D000970:Antineoplastic Agents; D000975:Antioxidants; D012333:RNA, Messenger; D013440:Sulfides; C042577:diallyl trisulfide; D053148:Caspase 3